|Bid||2.510 x 400|
|Ask||2.520 x 400|
|Day's Range||2.507 - 2.560|
|52 Week Range||0.940 - 3.200|
|PE Ratio (TTM)||-12.38|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 5 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Junior biotechs are attracting strong speculative interest that could offer outstanding returns for traders with well-honed risk management skills.
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has finally found some reprieve. Said reprieve comes in the form of some data just put out relating to the company’s lead development candidate (although not related to said candidate’s lead indication directly) and Catalyst is running […]
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 5 cents. For the year, the company reported that its loss widened to $18.1 million, or 22 cents per share. In the final ...
All three major indexes are in the green today as investors look forward to today’s FOMC meeting decision. Among the stocks that are also in bull-mode are Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Capital Bank Financial Corp (NASDAQ:CBF), Msci Inc (NYSE:MSCI), Finisar Corporation (NASDAQ:FNSR), and Whiting Petroleum Corp (NYSE:WLL). Let’s find out why traders are hitting the buy […]
Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study. The drug, Firdapse, was being tested on seven patients with Musk-MG, a rare subpopulation of MG patients. There are currently no therapies for this form of MG approved by the U.S. Food and Drug Administration (FDA).
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
Alexion Pharmaceuticals, Inc. (ALXN) revealed new long-term data from an ongoing, open-label extension of the pivotal phase III ARISE study on Kanuma
After initial NDA submission for Firdapse was rejected by the FDA earlier this year, the new agreement suggests approval may be forthcoming.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) just announced that it is carrying forward with a special protocol assessment (SPA) for its lead asset, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), in the second of two planned phase 3 investigations that will underpin a new drug application for the treatment. The company is up on the […]